Tremblay Michael
Tremblay Consulting, Cassis Ltd., Canterbury, Kent, UK.
Curr Drug Saf. 2013 Feb;8(1):43-55. doi: 10.2174/1574886311308010007.
The paper begins by asking why there is a market for counterfeit medicines, which in effect creates the problem of counterfeiting itself. Contributing factors include supply chain complexity and the lack of whole-systems thinking. These two underpin the author's view that counterfeiting is a complex (i.e. wicked) problem, and that corporate, public policy and regulatory actions need to be mindful of how their actions may be causal. The paper offers a problem-based review of key components of this complexity, viz., the knowledge end-users/consumers have of medicines; whether restrictive information policies may hamper information provision to patients; the internet's direct access to consumers; internet-enabled distribution of unsafe and counterfeit medicines; whether the internet is a parallel and competitive supply chain to legitimate routes; organised crime as an emerging medicines manufacturer and supplier and whether substandard medicines is really the bigger problem. Solutions respect the perceived complexity of the supply chain challenges. The paper identifies the need to avoid technologically-driven solutions, calling for 'technological agnosticism'. Both regulation and public policy need to reflect the dynamic nature of the problem and avoid creating perverse incentives; it may be, for instance, that medicines pricing and reimbursement policies, which affect consumer/patient access may act as market signals to counterfeiters, since this creates a cash market in cheaper drugs.
本文开篇提出为何存在假药市场的问题,而这实际上造就了造假问题本身。促成因素包括供应链的复杂性以及缺乏整体系统思维。这两点支撑了作者的观点,即造假是一个复杂(即棘手)的问题,企业、公共政策和监管行动需要留意其行动可能产生的因果关系。本文针对这种复杂性的关键要素进行了基于问题的综述,即终端用户/消费者对药品的了解;限制性信息政策是否会妨碍向患者提供信息;互联网使消费者能够直接获取信息;通过互联网分销不安全和假冒药品;互联网是否构成与合法渠道并行且具有竞争力的供应链;有组织犯罪成为新兴的药品制造商和供应商,以及不合格药品是否真的是更严重的问题。解决方案考虑到了供应链挑战的复杂性。本文指出有必要避免技术驱动的解决方案,提倡“技术不可知论”。监管和公共政策都需要反映问题的动态性质,避免产生不良激励;例如,影响消费者/患者获取药品的药品定价和报销政策可能会向造假者发出市场信号,因为这会催生低价药品的现金市场。